Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:bupropion
gptkb:naltrexone |
| gptkbp:approvalYear |
2014
|
| gptkbp:approvedBy |
gptkb:FDA
adults with obesity overweight adults with weight-related medical problems |
| gptkbp:contraindication |
pregnancy
eating disorders uncontrolled hypertension chronic opioid use seizure disorder use of other bupropion-containing products |
| gptkbp:drugClass |
anorexiant
antidepressant combination |
| gptkbp:form |
extended-release tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Contrave
|
| gptkbp:indication |
weight management
|
| gptkbp:manufacturer |
Currax Pharmaceuticals
|
| gptkbp:marketedIn |
gptkb:United_States
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:riskFactor |
seizures
suicidal thoughts |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting constipation dizziness headache insomnia dry mouth increased blood pressure |
| gptkbp:bfsParent |
gptkb:Orexigen_Therapeutics
|
| gptkbp:bfsLayer |
7
|